Frontline mRCC Treatment in 2025: Translating Long-Term Data Into Practice
The treatment landscape for metastatic renal cell carcinoma has undergone a fundamental transformation since 2018, transitioning from VEGF-targeted monotherapy to immunotherapy-based combinations. Current treatment decisions are centered on dual immunotherapy (nivolumab plus ipilimumab) or immunotherapy plus VEGF inhibitor combinations. However, long-term data have revealed important nuances in treatment selection, and novel therapeutic strategies are under investigation.
